---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-042478"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2024-10-08T23:59:59+00:00"
generated_at: "2026-05-30T17:55:13.078836+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Avalo doses first patient in Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa

## Summary
- Phase 2 LOTUS trial enrolling ~180 adults with moderate to severe hidradenitis suppurativa.
- Two dose regimens of AVTX-009 vs placebo in 1:1:1 randomization over 16-week treatment phase.
- Primary endpoint: proportion achieving HiSCR75 at Week 16; topline data expected in 2026.
- CEO Garry Neil cited high potency potential for best-in-class treatment option.
- AVTX-009 is a humanized monoclonal antibody targeting IL-1β with high affinity.

## SEC filing metadata
- accession: 0001628280-24-042478
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2024-10-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828024042478/0001628280-24-042478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828024042478/avtx-20241008.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-042478
- JSON: https://secwatch.observer/filing/0001628280-24-042478.json
- Plain text: https://secwatch.observer/filing/0001628280-24-042478.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.